Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Nucleosides, Nucleotides & Nucleic Acids|August 20, 2008
Novel enamine derivatives of 5,6-dihydro-2'-deoxyuridine formed in reductive amination of 5-formyl-2'-deoxyuridineElzbieta Sochacka, Damian Smuga
Molecules (Basel, Switzerland)|December 11, 2025
Development of Prediction Capabilities for High-Throughput Screening of Physiochemical Properties by Biomimetic ChromatographyDamian Tuz, Damian Smuga, Tomasz Pawiński
Talanta|May 22, 2012
An LC method for the analysis of phosphatidylcholine hydrolysis products and its application to the monitoring of the acyl migration processGrzegorz Kiełbowicz, Damian Smuga, Witold Gładkowski, et al.
Journal of Inorganic Biochemistry|February 23, 2010
Histamine modified 2'-deoxyriboadenosine--potential copper binding site in DNAzymesElzbieta Łodyga-Chruścińska, Elzbieta Sochacka, Damian Smuga, et al.
European Journal of Medicinal Chemistry|June 6, 2018
Synthesis and characterization of novel classes of PDE10A inhibitors - 1H-1,3-benzodiazoles and imidazo[1,2-a]pyrimidinesRafał Moszczyński-Pętkowski, Jakub Majer, Małgorzata Borkowska, et al.
Molecular Pharmacology|August 5, 2021
CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic AnimalsKatarzyna Bazydlo-Guzenda, Pawel Buda, Mikolaj Matloka, et al.
Plos One|July 24, 2020
Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of AsthmaPaweł Gunerka, Kamila Gala, Martyna Banach, et al.
European Journal of Medicinal Chemistry|September 19, 2021
Discovery and development of CPL207280 as new GPR40/FFA1 agonistMateusz Mach, Katarzyna Bazydło-Guzenda, Paweł Buda, et al.
Frontiers in Pharmacology|April 10, 2026
Preclinical evaluation of CPL423: a novel potent small-molecule inhibitor of TAM family and FLT3 kinase for cancer therapyAgata Mikołajczyk, Delfina Popiel, Kinga Jastrzębska, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2021
Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric AgonistsPiotr Pankiewicz, Marcin Szybiński, Katarzyna Kisielewska, et al.
Pageof 2